# Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

> **NCT04289285** · PHASE3 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 804 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** IBI306 450mg SC Q4W
- **DRUG:** Placebo SC Q4W
- **DRUG:** IBI306 600mg SC Q6W
- **OTHER:** Placebo SC Q6W

## Key facts

- **NCT ID:** NCT04289285
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-29
- **Primary completion:** 2022-02-09
- **Final completion:** 2022-02-09
- **Target enrollment:** 804 (ACTUAL)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04289285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04289285, "Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04289285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*